Rafael Holdings (RFL) Net Shares Issued and Repurchased (2020 - 2025)
Rafael Holdings' (RFL) quarterly Net Shares Issued and Repurchased came in at $24558.0 in Q4 2025, up 227.44% year-over-year from $7500.0 in Q4 2024, and down 93.78% quarter-over-quarter from $395000.0 in Q3 2025.
Analysis
Rafael Holdings (RFL) Net Shares Issued and Repurchased (2020 - 2025) Analysis & Trends
Rafael Holdings (RFL) has reported Net Shares Issued and Repurchased for 6 consecutive years, with $24558.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Net Shares Issued and Repurchased rose 227.44% year-over-year to $24558.0 in Q4 2025; TTM through Oct 2025 was $24558.0, a 227.44% increase from a year earlier, with the FY2025 full-year figure at $395000.0, up 58.0% from the prior year.
- Net Shares Issued and Repurchased was $24558.0 for Q4 2025 at Rafael Holdings, down from $395000.0 in the prior quarter.
- Over five years, Net Shares Issued and Repurchased peaked at $98.0 million in Q4 2021 and troughed at $7500.0 in Q4 2024.
- A 5-year average of $16.6 million and a median of $273379.5 in 2023 frame the typical range for Net Shares Issued and Repurchased.
- Across the five-year window, Net Shares Issued and Repurchased surged 4668789.95% in 2021 and slumped 99.96% in 2023, its largest moves.
- Over 5 years, Net Shares Issued and Repurchased stood at $98.0 million in 2021, then changed by 0.0% to $98.0 million in 2022, then tumbled by 99.96% to $43878.0 in 2023, then sank by 82.91% to $7500.0 in 2024, then surged by 227.44% to $24558.0 in 2025.
- The last three Net Shares Issued and Repurchased figures came in at $24558.0 (Q4 2025), $395000.0 (Q3 2025), and $7500.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 31, 2025 | 24,558.00 |
| Jul 31, 2025 | 395,000.00 |
| Oct 31, 2024 | 7,500.00 |
| Jul 31, 2024 | 250,000.00 |
| Oct 31, 2023 | 43,878.00 |
| Jul 31, 2023 | 589,205.00 |
| Jan 31, 2023 | 296,759.00 |
| Oct 31, 2022 | 98.00 Mn |
| Jul 31, 2022 | 943,305.00 |
| Oct 31, 2021 | 98.00 Mn |
| Jul 31, 2021 | 118,409.00 |
| Apr 30, 2021 | 118,409.00 |
| Oct 31, 2020 | 2,099.00 |
| Jul 31, 2020 | 333.00 |